The tolerability and efficacy of immunotherapy (either alone or in combination treatment) remains largely unknown in patients living with HIV on antiretrovirals (ART), who had generally been excluded from previous trials. We recently compiled one of the largest experiences among patients with HIV infection and lung cancer. Our data showed a remarkably low expression of PD- L1 in this patient population. We also found that alternative immune checkpoints were widely expressed in solid tumors. Intriguingly, the majority of PD-L1 negative lung cancers expressed alternative immune checkpoints, implicating their potential roles in mediating immune escape mechanisms within the tumor microenvironment, apart from the PD-1/PD-L1 axis. As an anti-angiogenic agent, Cabozantinib is also associated with an immune permissive tumor environment with immune-stimulatory activities. Its antitumor activity has been observed in thyroid cancer, renal cell and hepatocellular carcinomas, as well as Kaposi sarcoma (KS) and other solid tumors. The combination of Cabozantinib with Nivolumab may modify the tumor microenvironment and reverse the resistance to immunotherapy. In the proposed study, we will determine the safety profile and clinical benefits of the combined treatment with Nivolumab and Cabozantinib in HIV infected patients with advanced solid tumors (especially KS). The Primary objectives are to determine the safety of combined Nivolumab and Cabozantinib in HIV patients with advanced solid tumors and to determine the feasibility to deliver the combined Nivolumab and Cabozantinib (40mg daily) for a minimum of 4 cycles in at least 75% of the subjects or to achieve a confirmed objective response. Six patients will be enrolled in the safety run-in cohort. At the expansion cohort, 12 additional subjects with KS would be enrolled to gather more data on safety and correlative studies. We will also conduct correlative analyses to expand our understanding of the underlying biology, predictive biomarkers and treatment resistance in this group of patients. We expect that the combined treatment of Nivolumab and Cabozantinib is safe and feasible in HIV patients with solid tumors. Moreover, we anticipate that the combination has clinical activity in this unique and understudied patient population.

Public Health Relevance

The tolerability and efficacy of immunotherapy (either alone or in combination treatment) remains largely unknown in patients living with HIV on antiretrovirals (ART), who had generally been excluded from previous trials. In the proposed study, we will determine the safety profile and clinical benefits of the combined treatment with Nivolumab and Cabozantinib in HIV infected patients with advanced solid tumors (especially Kaposi sarcoma). We will also conduct correlative analyses to expand our understanding of the underlying biology, predictive biomarkers and treatment resistance in this unique and understudied patient population.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013330-48S3
Application #
10227387
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-06-01
Project End
2022-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
48
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
081266487
City
Bronx
State
NY
Country
United States
Zip Code
10461
Zamurrad, Sumaira; Hatch, Hayden A M; Drelon, Coralie et al. (2018) A Drosophila Model of Intellectual Disability Caused by Mutations in the Histone Demethylase KDM5. Cell Rep 22:2359-2369
Sparano, Joseph A (2018) Prognostic gene expression assays in breast cancer: are two better than one? NPJ Breast Cancer 4:11
Centini, Ryan; Tsang, Mark; Iwata, Terri et al. (2018) Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation. PLoS One 13:e0197973
Nadaradjane, Celine; Yang, Chia-Ping Huang; Rodriguez-Gabin, Alicia et al. (2018) Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners. J Nat Prod 81:607-615
Tiwari, Sangeeta; van Tonder, Andries J; Vilchèze, Catherine et al. (2018) Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 115:9779-9784
Celestrin, Kevin; Díaz-Balzac, Carlos A; Tang, Leo T H et al. (2018) Four specific immunoglobulin domains in UNC-52/Perlecan function with NID-1/Nidogen during dendrite morphogenesis in Caenorhabditis elegans. Development 145:
Haider, Afreen; Wei, Yu-Chen; Lim, Koini et al. (2018) PCYT1A Regulates Phosphatidylcholine Homeostasis from the Inner Nuclear Membrane in Response to Membrane Stored Curvature Elastic Stress. Dev Cell 45:481-495.e8
Cai, Ying; Lin, Jhih-Rong; Zhang, Quanwei et al. (2018) Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer. Sci Rep 8:5535
Li, Ke; Baker, Nicholas E (2018) Regulation of the Drosophila ID protein Extra macrochaetae by proneural dimerization partners. Elife 7:
Xie, Xianhong; Xue, Xiaonan; Strickler, Howard D (2018) Generalized linear mixed model for binary outcomes when covariates are subject to measurement errors and detection limits. Stat Med 37:119-136

Showing the most recent 10 out of 1508 publications